Skip to main content

ENDOless

Category: AI in Healthcare

An AI-powered mobile application for women with endometriosis to track symptoms, receive personalized insights, and contribute to research. ENDOless was founded in 2024. The company is led by Alexandra Mont. Based in Paris, France. Team size: 1-10. Total funding raised: €75,000 grant from the European Commission's Women TechEU program, plus an unspecified grant from the 'Lazio Innova' pre-seed call. Currently pursuing €2 million seed round.. Latest round: Pre-Seed / Grant. Key investors include European Commission (Women TechEU), Lazio Innova.

Founded
2024
Headquarters
Paris, France
Team size
1-10
Total funding
€75,000 grant from the European Commission's Women TechEU program, plus an unspecified grant from the 'Lazio Innova' pre-seed call. Currently pursuing €2 million seed round.

Value proposition

To empower women with endometriosis to take control of their condition through AI-powered predictions and personalized insights, helping them to thrive rather than just survive.

Products and solutions

ENDOless Mobile Application

Unique value

ENDOless uniquely combines symptom tracking with AI-driven predictive insights to help users anticipate and manage endometriosis flare-ups. It also aims to build a community and contribute to research, turning individual pain points into collective power.

Target customer

Women diagnosed with or suspecting they have endometriosis.

Industries served

Healthcare, FemTech, Digital Health

Technology advantage

The core technological advantage lies in its proprietary AI algorithms that analyze user data to provide personalized and predictive health management. The business advantage is its focus on a historically underserved and poorly understood chronic condition, creating a strong, engaged user base.

How they differentiate

ENDOless differentiates itself by offering a comprehensive digital platform that connects patients and clinicians. The platform includes a symptom-tracking app for patients and a dashboard for doctors, aiming to create a multidisciplinary and personalized therapeutic path. It uses AI to correlate symptoms, habits, and therapies to predict pain onset, moving beyond simple tracking or diagnostics to offer a full-cycle management solution.

Main competitors

Endometrix, Ziwig, Demetria

Key partnerships

Information not publicly available.

Notable customers

Not publicly available. The company is in its early stages and has not announced any notable customers or case studies.

Major milestones

Selected for the 'Women TechEU' program by the European Commission., Received a grant from the 'Lazio Innova' pre-seed call., Finalist in the 'Start Cup' competition of the Lombardy Region., Development of their digital platform, including a patient app and a clinician dashboard., Selected as one of the most impactful innovations at ChangeNOW 2025., Opened a seed round in May 2025 targeting €2 million.

Growth metrics

Not publicly available. As an early-stage startup, ENDOless has not yet disclosed any public growth metrics.

Market positioning

ENDOless is positioned as a deeptech women's health platform for the management of chronic gynecological conditions, with an initial focus on endometriosis. It aims to be a holistic solution for disease management rather than just a diagnostic or symptom tracking tool.

Geographic focus

The company is based in Paris, France, and its primary competitive focus appears to be on the European market.

Patents and IP

Information not publicly available.

About Alexandra Mont

Previously served as a Senior Project Manager at GE HealthCare (2015-2024), with a background in R&D engineering in the medical imaging field. She holds a Master's degree in Engineering from INSA Lyon and a Specialised Master's in Project and Program Management from SKEMA Business School.

Official website: